BDRX — Biodexa Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $2.38m
- -$4.74m
- £0.38m
Annual cashflow statement for Biodexa Pharmaceuticals, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -10.1 | -22.2 | -5.46 | -7.66 | -7.08 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -1.41 | 11.3 | -1.49 | -0.933 | -0.826 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.72 | 0.396 | 0.54 | 1.2 | 0.796 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -6.49 | -9.3 | -6.01 | -7.05 | -6.83 |
| Capital Expenditures | -0.319 | -0.209 | -0.32 | -0.062 | -0.263 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -3.49 | 2.78 | 0.042 | -0.158 | -0.002 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3.81 | 2.57 | -0.278 | -0.22 | -0.265 |
| Financing Cash Flow Items | 1.22 | 0.011 | -0.015 | -0.018 | -0.013 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 18.7 | 3.08 | 8.8 | 0.047 | 10.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 8.59 | -3.38 | 2.51 | -7.22 | 3.13 |